CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
MEK 抑制缓解巨噬细胞过度活化且不损害 CAR-T 细胞治疗疗效
英文原题：MEK inhibition alleviates macrophage overactivation without compromising the efficacy of CAR-T-cell therapy.
查看英文原题
MEK inhibition alleviates macrophage overactivation without compromising the efficacy of CAR-T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本研究提出抑制丝裂原活化蛋白激酶激酶（MEK）作为嵌合抗原受体（CAR）T细胞治疗相关细胞因子释放综合征（CRS）和继发性噬血细胞性淋巴组织细胞增多症（sHLH）的策略。其依据是MEK可调节巨噬细胞活化及巨噬细胞和CAR-T 细胞的细胞因子分泌；研究证据还显示，在减轻CAR-T 相关炎症的同时，CAR-T 治疗效力未受损。
展开英文摘要原文
This study presents mitogen-activated protein kinase kinase (MEK) inhibition as a strategy for cytokine release syndrome (CRS) and secondary haemophagocytic lymphohistiocytosis (sHLH) in chimeric antigen receptor (CAR)-T therapy, utilizing MEK's regulatory actions that target macrophage activation, cytokine secretion from both macrophages and CAR-T cells, supported by evidence of unimpaired CAR-T-cell therapeutic efficacy of alleviated CAR-T-related inflammation.
论文信息
- 作者
- Li H、Wang Y、Wang Y、Ding L、Li S、Wu M、Xu Q、Chen Y
- 单位
- Department of Hematology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.China
- 期刊
- British journal of haematology2026 Apr
- 原文标识
- PubMed 41705802 · DOI 10.1111/bjh.70364